U.S., Dec. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07308067) titled 'Kinetics of Transmural Healing in Patients With Crohns Disease Treated With Risankizumab (SKYRIZI(R))' on Dec. 15.
Brief Summary: Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) that can highly alter patients' quality of life and lead to bowel damage due to its transmural pattern. The current guidelines recommend to use treat-to-target strategies to achieve the combination of steroid-free clinical remission and endoscopic remission. However, the implementation of these strategies and endpoints are limited by the need of repeated colonoscopies, which dramatically reduced patients' acceptability and adherence to suc...